2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
41
Carcinoma, Non-Small-Cell Lung
31
Triple Negative Breast Neoplasms
23
Nasopharyngeal Carcinoma
23
Stomach Neoplasms
22
Esophageal Neoplasms
20
Esophageal Squamous Cell Carcinoma
19
Breast Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
14
Uterine Cervical Neoplasms
12
Colorectal Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Lung Neoplasms
9
Recurrence
7
Neoplasm Metastasis
7
Melanoma
6
Liver Neoplasms
6
Hodgkin Disease
6
Cholangiocarcinoma
6
Biliary Tract Neoplasms
5
Advanced Gastric Cancer
5
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Neoplasms
4
Locally Advanced Gastric Cancer
4
Advanced Solid Tumor
4
Solid Tumor
3
Respiratory Tract Diseases
3
Rectal Neoplasms
3
Interventions
pembrolizumab
10
Nivolumab
9
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
sintilimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
camrelizumab
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled